MG冰球突破官网

Media

Press Release

09
2022.11
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV
27
2022.10
Acceptance Of The Application For Clinical Trial Of Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
19
2022.08
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
10
2022.08
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

Publications

2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques
欧博体育登录入口 体育在线网投地址 靠谱的足球滚球app软件 正规买足球平台主页 im体育注册主页 宝博体育app官方 美国体育博彩首页歡迎您 世界杯靠谱买入口 og体育开户亚洲官网 >网站地图-sitemap